Hyperglycemia on Admission Is Associated With Worse Outcomes and Severity of Illness in Critically Ill COVID-19 Patients
Conference Paper
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
Rationale Hyperglycemia is a multifactorial condition. In COVID-19 pneumonia, worse outcomes have been described inpatients with hyperglycemia. This study aimed to describe the relationship between hyperglycemia, increased APACHE, SOFA,and Ichikado CT scores on admission and mortality. METHODS Retrospective study of patients admitted to our hospital withcritical COVID-19 pneumonia from March 2020 to February 2022. We divided patients into 2 groups: Group 1 (G1) hadhyperglycemia (>180mg/dL) on admission and group 2 (G2) did not. Demographics, blood glucose on admission and adverseevents during hospitalization were recorded. Mann-Whitney-U test, Chi-square, and Fisher’sexact test were utilized to ascertainstatistical significance. RESULTS 195 patients with hyperglycemia on admission were analyzed. Patients from G1 were olderthan those of G2 [59 years (50-68) vs. 54 years (43-66)] (p<0.001), had higher prevalence of hypertension [98 (50.5%25) vs.270(33.8%25)] (p <0.001), type 2 diabetes mellitus [126 (64.9%25) vs. 125 (15.7%25)] (p <0.001), and a higher BMI [39.4 (26.6. 29.2(25.8-34.3)] (p =0.033). On admission, G1 had higher APACHE [11(7-15) vs. 8(5-12)] (p<0.001), SOFA [2(2-3) vs. 2(1-3)](p=0.001), and Ichikado CT scores [(125-210) vs.150 (120-190)] (p=0.015). Deep vein thrombosis (DVT) [5(2.6%25) vs. 4(0.5%25)](p=0.006), and congestive heart failure (CHF) [9(4.6%25) vs. 14(1.1%25)] (p=0.017) was more frequent in G1 Mortality was higher inG1 (56[28.7%25) vs. 131(16.4%25)] (p<0.001). (95%25 CI [1.43-2.95]). There was a significant difference in the odds of death betweenhyperglycemia and normoglycemia on admission (OR=2.05, 95%25 CI [1.43-2.95]) (p<0.001). CONCLUSIONS Hyperglycemia onadmission is associated with higher APACHE, SOFA, Ichikado scores. In addition, it is associated with higher rates of DVT,CHF and mortality in hospitalized COVID-19 patients.
